High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma.
PXR
breast cancer
cell lines
clinicopathological parameters
immunohistochemistry
patients’ prognosis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
20 Oct 2021
20 Oct 2021
Historique:
received:
22
09
2021
revised:
12
10
2021
accepted:
15
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Pregnane X Receptor (PXR) is involved in human cancer, either by directly affecting carcinogenesis or by inducing drug-drug interactions and chemotherapy resistance. The clinical significance of PXR expression in invasive breast carcinoma was evaluated in the present study. PXR protein expression was assessed immunohistochemically on formalin fixed paraffin-embedded breast invasive carcinoma tissue sections, obtained from 148 patients, and was correlated with clinicopathological parameters, molecular phenotypes, tumor cells' proliferative capacity, and overall disease-free patients' survival. Additionally, the expression of PXR was examined on human breast carcinoma cell lines of different histological grade, hormonal status, and metastatic potential. PXR positivity was noted in 79 (53.4%) and high PXR expression in 48 (32.4%), out of 148 breast carcinoma cases. High PXR expression was positively associated with nuclear grade (
Identifiants
pubmed: 34829293
pii: diagnostics11111946
doi: 10.3390/diagnostics11111946
pmc: PMC8624096
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Cancer. 2011 Feb 22;11:81
pubmed: 21342487
Acta Pharm Sin B. 2020 Feb;10(2):197-206
pubmed: 32082968
Hepatology. 2008 Apr;47(4):1277-87
pubmed: 18167061
Histopathology. 2016 Jan;68(1):70-85
pubmed: 26768030
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):847-57
pubmed: 17125405
J Clin Invest. 2005 Jan;115(1):177-86
pubmed: 15630458
Pharmacogenomics. 2016 Sep;17(14):1547-71
pubmed: 27561454
Mol Pharmacol. 2007 Oct;72(4):1045-53
pubmed: 17636047
Gastroenterology. 2006 Jul;131(1):194-209
pubmed: 16831602
Oncogene. 2015 Oct 16;34(42):5309-16
pubmed: 25703331
J Clin Invest. 1998 Sep 1;102(5):1016-23
pubmed: 9727070
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):895-908
pubmed: 18624678
Cancer Biol Ther. 2009 Jul;8(13):1265-72
pubmed: 19746521
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1257-64
pubmed: 20691230
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Arch Pathol Lab Med. 2010 Jun;134(6):907-22
pubmed: 20524868
Cells. 2020 Oct 15;9(10):
pubmed: 33076284
Hum Pathol. 1995 Aug;26(8):873-9
pubmed: 7635449
Oncol Lett. 2013 Apr;5(4):1093-1100
pubmed: 23599746
Cancer Treat Rev. 2007 Jun;33(4):369-80
pubmed: 17451886
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
BMC Gastroenterol. 2011 Oct 06;11:108
pubmed: 21977915
BMC Cancer. 2008 Jun 19;8:174
pubmed: 18565212
Cancer. 2007 Mar 1;109(5):957-65
pubmed: 17279585
Cancer Lett. 2013 Jan 1;328(1):1-9
pubmed: 22939994
Pharmacol Res. 2011 Jul;64(1):4-10
pubmed: 21397695
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):251-65
pubmed: 15364541
Cell Signal. 2008 Dec;20(12):2180-97
pubmed: 18634871
Mol Endocrinol. 2007 Jan;21(1):138-47
pubmed: 16973756
Cancers (Basel). 2020 Oct 10;12(10):
pubmed: 33050543
Antivir Ther. 2004 Oct;9(5):819-21
pubmed: 15535420
Biochem Pharmacol. 2005 Sep 15;70(6):949-58
pubmed: 16054595
Cancer Res. 2006 Jan 1;66(1):535-42
pubmed: 16397270
Cancers (Basel). 2020 Aug 25;12(9):
pubmed: 32854297
Mol Aspects Med. 2009 Oct;30(5):297-343
pubmed: 19427329
J Clin Endocrinol Metab. 2003 Sep;88(9):4446-54
pubmed: 12970323
Histopathology. 2011 Jan;58(2):246-53
pubmed: 21323950
Pancreas. 2015 Oct;44(7):1134-40
pubmed: 26355550
Endocr Relat Cancer. 2007 Jun;14(2):293-303
pubmed: 17639045
Mol Endocrinol. 2005 May;19(5):1170-80
pubmed: 15650019
Inflamm Bowel Dis. 2007 Dec;13(12):1484-7
pubmed: 17828778
Mol Cancer. 2010 Mar 02;9:46
pubmed: 20196838
Mol Pharm. 2008 Jan-Feb;5(1):60-6
pubmed: 18072748
Histol Histopathol. 2013 Apr;28(4):405-20
pubmed: 23413096
Mol Cancer. 2011 Jul 06;10:80
pubmed: 21733184
Mol Pharmacol. 2008 Apr;73(4):1282-9
pubmed: 18187584
Biomolecules. 2021 Aug 02;11(8):
pubmed: 34439808
BJU Int. 2011 Jun;107(11):1833-8
pubmed: 20840328
Clin Cancer Res. 1999 Aug;5(8):2103-7
pubmed: 10473093
Pathol Int. 2010 May;60(5):400-6
pubmed: 20518891
Genes Dev. 1992 Mar;6(3):329-44
pubmed: 1312497
Pathol Res Pract. 2014 Aug;210(8):533-40
pubmed: 24947414
Cancer Sci. 2012 Feb;103(2):176-80
pubmed: 22050110
Cancer Res. 2008 Nov 15;68(22):9338-47
pubmed: 19010908
Mol Cell Biol. 2007 Nov;27(22):7947-54
pubmed: 17875939
Histopathology. 2013 May;62(6):899-907
pubmed: 23551536
Oncol Lett. 2013 Mar;5(3):835-839
pubmed: 23443531
Breast Cancer Res. 2019 Dec 3;21(1):132
pubmed: 31796128
Drug Metab Dispos. 2007 Jul;35(7):1032-41
pubmed: 17392393
Cancer Sci. 2010 Feb;101(2):543-9
pubmed: 19860844
Curr Drug Metab. 2013 Mar;14(3):341-50
pubmed: 23237007